Justin Austin

[Justin Austin @ConferenceHype]

@ConferenceHype

[Hidehito HORINOUCHI @HHorinouchi]

🆙 @OncoAlert #ASCO26 #LCSM 🔝🔟Abstracts
Leads: @HHorinouchi @UOzkerim @WeOncologists
1 HARMONi-6
2 LIBRETTO-432
3 WU-KONG28
4 OptiTROP-Lung05
5 TRITON
6 CROWN 7yr
7 LORIN
8 AcceleRET-Lung
9 Silevertinib
10 Concurrent CRT + durvalumab in ES-SCLC
@ASCO @Larvol

[Justin Austin @ConferenceHype]

@ConferenceHype

[OncoAlert @OncoAlert]

The OncoAlert🚨 GU faculty’s TOP 10 abstracts In GU Oncology for #ASCO26 are here — selected by our leads and finalized through a Delphi voting process with our senior GU cancer experts across #ProstateCancer #KidneyCancer #BladderCancer .
A snapshot of what will shape GU oncology at #ASCO26 👇

1️⃣ LBA5007 — TALAPRO-3
Talazoparib + enzalutamide vs placebo + enzalutamide in mCSPC with HRR alterations

2️⃣ LBA1 — PROTEUS
Perioperative apalutamide + ADT vs ADT in high-risk localized/locally advanced prostate cancer (final Phase 3)

3️⃣ 5001 — ENZAMET genomic analysis
Decipher >0.85 to identify benefit from adding docetaxel to ADT + enzalutamide

4️⃣ LBA4511 — KEYNOTE-564 ctDNA
ctDNA dynamics in RCC treated with adjuvant pembrolizumab vs placebo

5️⃣ 4502 — RAMPART
Durvalumab vs active monitoring after resection in RCC (Phase 3 RCT)

6️⃣ 4500 — RADICAL (A031801)
Radium-223 + cabozantinib in RCC with bone metastases

7️⃣ 4507 — EV-302 long-term follow-up
Enfortumab vedotin + pembrolizumab vs chemotherapy in 1L LA/mUC

8️⃣ 4513 — AMBASSADOR (A031501)
HRQoL with adjuvant pembrolizumab vs observation in high-risk MIBC

9️⃣ 4503 — SAKK 06/19
Perioperative intravesical rBCG + chemo-IO strategy in MIBC (primary analysis)

🔟 4510 — KEYNOTE-905
HRQoL with perioperative enfortumab vedotin + pembrolizumab in cisplatin-ineligible MIBC

Leads
@nataliagandur
@scocmem
@AmandaNizamMD
@WeOncologists

Senior Faculty
@montypal @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @neerajaiims @amerseburger @Silke_Gillessen
@tompowles1 @AndreaNecchi @cdanicas @AOmlin

Pinging
@crisbergerot @HHammersMD @ravikanesvaran @sonpavde @drenriquegrande @scserendipity1 @EfstathiouEleni @BraunMDPhD @brian_rini

[Justin Austin @ConferenceHype]

@ConferenceHype

[OncoAlert @OncoAlert]

The OncoAlert🚨 GI faculty’s TOP 10 abstracts In GI Oncology for #ASCO26 are here — selected by our leads and finalized through a Delphi voting process with our senior experts across #ColorectalCancer #ColonCancer #LiverCancer #PancreaticCancer and more
A snapshot of what will shape GI oncology at #ASCO26 👇

🚨 OncoAlert Top 10 — #GIcancer at #ASCO26
1️⃣ LBA5 | RASOLUTE 302 — Daraxonrasib vs chemo in previously treated metastatic pancreatic adenocarcinoma
2️⃣ #4017 | FIGHT-302 — Pemigatinib in untreated unresectable/metastatic FGFR2-rearranged cholangiocarcinoma (Ph3)
3️⃣ LBA4000 | EMERALD-3 — Tremelimumab + durvalumab + lenvatinib + TACE in unresectable HCC (Ph3)
4️⃣ #3506 | PUMP Trial — Adjuvant HAIP floxuridine in resectable colorectal liver metastases
5️⃣ LBA3500 | CIRCULATE — ctDNA-guided adjuvant therapy in Stage II colon cancer
6️⃣ LBA3503 | BREAKWATER — Encorafenib + cetuximab + FOLFIRI as 1L in BRAF V600E mCRC (Ph3)
7️⃣ LBA3508 | EPISODE-III — Adjuvant aspirin vs placebo in Stage III CRC post-resection (Ph3)
8️⃣ #3505 — Trastuzumab rezetecan vs SOC in chemo-refractory HER2+ advanced CRC (Ph3)
9️⃣ #4006 | ATTRACTION-6 — Nivo + ipi + chemo as 1L in HER2− advanced gastric/GEJ cancer
🔟 #3504 | SWOG S2107 — Encorafenib + cetuximab + nivo in MSS BRAF V600E mCRC (Ph2)

Leads
@realbowtiedoc
@p_ciracimd
@WeOncologists

Senior faculty
@CathyEngMD @ARosen380 @GillSharlene @BenWestphalen @graokane

Participating AF
@DrVilmaPBarcia @Erman_Akkus @GIMedOnc

[Justin Austin @ConferenceHype]

@ConferenceHype

[Paolo Tarantino @PTarantinoMD]

Only few days to #ASCO26. For breast oncologists, this edition will deliver a new promising biomarker to spare unnecessary chemo, informative updates from practice-changing trials across subtypes, and major innovations coming from China. See you in Chicago next week! #bcsm

[Justin Austin @ConferenceHype]

@ConferenceHype

[Dr. Estela Rodriguez @Latinamd]

Here are my own #ASCO26 Top 10 🫁 Lung Cancer Abstracts based on potential clinical impact — although there is so much exciting and innovative science being presented across the field. Looking forward to the discussions, debates, and future directions these data may inspire. #LungCancer

[Justin Austin @ConferenceHype]

@ConferenceHype

[Raffaele Colombo @raffcolo]

🚨 39 oral and rapid oral ADC abstracts will be presented at #ASCO26 (up from 36 abstracts in 2025)!

ADC-related posters (excluding trial in progress) jumped from 78 in 2025 to 119 in 2026!

Here all the 39 oral and rapid oral presentations 👇

@ASCO #ADCs

[Raffaele Colombo @raffcolo]

🚨 39 oral and rapid oral ADC abstracts will be presented at #ASCO26 (up from 36 abstracts in 2025)!

ADC-related posters (excluding trial in progress) jumped from 78 in 2025 to 119 in 2026!

Here all the 39 oral and rapid oral presentations 👇

@ASCO #ADCs

[Justin Austin @ConferenceHype]

@conferencehype #ASCO26 Welcome to our AI coverage of ASCO 2026. If you are unable to attend follow along. If you are there or are an exibitor have a blast and tag #ASCOHype for the AI to pick it up and maybe give you a shout out...